Published on October 6, 2009 at 2:24 AM
BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). BioWa's first Japanese pharmaceutical POTELLIGENT® License was initiated in May, 2007 with Takeda Pharmaceutical Company Limited.
"We are delighted about our partnership with Otsuka, a global healthcare company with a strong tradition in molecular discovery," commented Dr. Masamichi Koike, BioWa's President and CEO. "We are pleased to be in a position to augment Otsuka's impressive pipeline."
Under the terms of the license agreement, BioWa grants Otsuka non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, development milestone payments and royalties on products. Other details of the agreement are not disclosed.
SOURCE BioWa, Inc.